PR Newswire
Live video webcast on
Wednesday, January 18
th
at
10:00 AM ET
HOUSTON
,
January 5, 2023
/PRNewswire/ —
CNS Pharmaceuticals, Inc.
(NASDAQ: CNSP) (“CNS” or the “Company”), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that
John Climaco
, Chief Executive Officer
of CNS Pharmaceuticals will present at the
Virtual Investor 2023 Companies to Watch Event
on
Wednesday, January 18, 2023
at
10:00 AM ET
.
A
live video webcast
of the presentation will be available on the
Events
page of the
Investors
section of the Company’s website (
cnspharma.com
). A webcast replay will be available two hours following the live presentation and will be accessible for 90 days.
About CNS Pharmaceuticals, Inc.
CNS Pharmaceuticals a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system. The Company’s lead drug candidate, Berubicin, is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. Berubicin is currently in development for the treatment of a number of serious brain and CNS oncology indications including glioblastoma multiforme (GBM), an aggressive and incurable form of brain cancer.
For more information, please visit
www.CNSPharma.com
, and connect with the Company on
Twitter
,
Facebook
, and
LinkedIn
.
View original content to download multimedia:
https://www.prnewswire.com/news-releases/cns-pharmaceuticals-to-present-at-the-virtual-investor-2023-companies-to-watch-event-301714427.html
SOURCE CNS Pharmaceuticals, Inc.
